

APASL Oncology 2023 in Sendai

“In Search of Silver Bullet for HCC”

Scientific Program



Scientific Program

Day 1: October 27 (Friday) 2023

Room 1 (Sendai A)

8:30-8:40 Opening Ceremony

Opening Remarks: Dr. Yoshiyuki Ueno, President of APASL Oncology 2023 Sendai

8:40-9:10 Opening Lecture

Chair: Dr. Yoshiyuki Ueno (Japan)

Challenge of Oncology with or without Driver Genes; Liver, Lung and Pancreas

Dr. Masao Omata (Japan)

9:10-10:10 Workshop 1: Systemic Chemotherapy & Oncology 1

Chairs: Dr. Shiv K Sarin (India), Dr. Naoya Kato (Japan), Dr. Ken Shirabe (Japan),

Dr. Tatsuya Yamashita (Japan)

9:10-9:22 WS1-1

Multimodal Treatment Strategy with Atezolizumab plus Bevacizumab towards the Complete Response in Unresectable Hepatocellular Carcinoma

Dr. Haruhiko Takeda (Japan)

9:22-9:34 WS1-2

Late Line Treatment with Atezolizumab plus Bevacizumab Therapy is Less Effective in Unresectable Hepatocellular Carcinoma

Dr. Masashi Ninomiya (Japan)

9:34-9:46 WS1-3

Comparative Analysis of Atezolizumab plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-center, Propensity Score Study

Dr. Pil Soo Sung (Korea)

9:46-9:58 WS1-4

Changes in Serum Growth Factors During Resistance to Ate-zolizumab Plus Bevacizumab Treatment in Patients with Un-resectable Hepatocellular Carcinoma

Dr. Goki Suda (Japan)

9:58-10:10 WS1-5

Predictive Factors for Durable Response in Patients Received Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma

Dr. Yutaka Yasui (Japan)

10:10-11:10 Workshop 2: Systemic Chemotherapy & Oncology 2

Chairs: Dr. Han-Chieh Lin (Taiwan), Dr. Masayuki Kurosaki (Japan),

Dr. Hidekatsu Kuroda (Japan), Dr. Masafumi Ikeda (Japan)

10:10-11:22 WS2-1

A Prospective Study to Assess the Safety and Efficacy of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma Aiming to Maximise Its Potential in Current Clinical Practice

Dr. Kazufumi Kobayashi (Japan)

11:22-11:34 WS2-2

Prognostic Factors for Survival in Patients with Intermediate-stage Unresectable Hepatocellular Carcinoma Treated with Lenvatinib or Atezolizumab plus Bevacizumab

Dr. Naoki Uchihara (Japan)

11:34-11:46 WS2-3

Immunokinetic Analysis Predicts Efficacy of Combination Immunotherapy for Advanced Hepatocellular Carcinoma

Dr. Takahiro Kodama (Japan)

11:46-11:58 WS2-4

Cabozantinib Therapy in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma-Importance of Good Liver Function and Good Performance Status

Dr. Teiji Kuzuya (Japan)

11:58-12:10 WS2-5

Therapeutic Strategy for Advanced Hepatocellular Carcinoma with Combination of Systemic Therapy and Surgical Resection

Dr. Takahiro Nishio (Japan)

11:20-11:40 Keynote Lecture 1

Chair: Ryosuke Tateishi (Japan)

Strategies for Preventing NASH-derived HCC

Dr. Grace L.H. Wong (China)

11:40-12:00 Keynote Lecture 2

Chair: Naoya Sakamoto (Japan)

Cholangiocarcinoma: Seeking a Cure

Dr. Gregory J. Gores (USA)

12:00-12:20 President Lecture

Chair: Dr. Masao Omata (Japan)

In Search of Silver Bullet for HCC

Dr. Yoshiyuki Ueno (Japan)

12:30-13:30 Luncheon Seminar 1 (Sponsored by Eisai Co., Ltd.)

Chair: Dr. Naoya Kato (Japan)

The Value of Lenvatinib, Synthesized in Japan, in Patients with HCC-including Harmonization with Loco-regional Therapy

12:30-13:00 LS1-1

Positioning of Lenvatinib and Role of Adding Hepatic Arterial Infusion Chemotherapy to Lenvatinib for Unresectable Hepatocellular Carcinoma in Era of Immunotherapy

Dr. Takeshi Terashima (Japan)

13:00-13:30 LS1-2

New Treatment Strategies for Unresectable HCC ~The Positioning of Lenvatinib in Real-world Practice~

Dr. Kaoru Tsuchiya (Japan)

13:40-14:10 Special Lecture 1

Chair: Dr. Masao Omata (Japan)

Management of Portal Hypertension in HCC

Dr. Shiv K. Sarin (India)

14:10-14:40 Special Lecture 2

Chair: Dr. Osamu Yokosuka (Japan)

Systemic Therapy for Hepatocellular Carcinoma-2023 and Beyond

Dr. George K.K. Lau (China)

14:40-15:10 Special Lecture 3

Chair: Satoshi Mochida (Japan)

Development of HCC in HBV Patients

Dr. Jia-Horng Kao (Taiwan)

15:20-15:40 Keynote Lecture 3

Chair: Dr. Osamu Yokosuka (Japan)

Biomarker-based Precision Medicine in the Era of Combination Immunotherapy in HCC

Dr. Takahiro Kodama (Japan)

15:40-16:40 Workshop 3: Liver Cirrhosis (Fibrosis) & Its Complications, NASH/ NAFLD

Chairs: Dr. Yoichi Hiasa (Japan), Dr. Shuji Terai (Japan), Dr. Kenichi Ikejima (Japan)

15:40-15:52 WS3-1

The Difference of Branched-chain Amino Acids Tyrosine Ratio (BTR) among Chronic Liver Disease Comparing to Healthy Adult

Dr. Eiji Kakazu (Japan)

15:52-16:04 WS3-2

Agile 3+ and Agile 4, Non-invasive Tests for Liver Fibrosis, are Excellent Formulae to Predict Liver-related Events in Nonalcoholic Fatty Liver Disease

Dr. Kouichi Miura (Japan)

16:04-16:16 WS3-3

Impact of Liver Fibrosis Severity on Oncological Prognosis in Hepatocellular Carcinoma: 1-to-1 Individual Case-matched Analysis

Dr. Koya Yasukawa (Japan)

16:16-16:28 WS3-4

Impact of Chemotherapy on Liver

Dr. Harshita Dubey (India)

16:28-16:40 WS3-5

Big Data Analysis of Fatty Liver, Liver Stiffness and Liver Cancer Frequency within Cancer Center Hospitals

Dr. Hitoshi Mochizuki (Japan)

18:10-19:10 Awarding Ceremony

19:10-20:30 Welcome Reception

Day 1: October 27 (Saturday) 2023

Room 2 (Sendai B)

9:10-10:10 Workshop 4: Basic Science & Pathology 1

*Chairs: Dr. Jin Mo Yang (Korea), Dr. Shinji Itoh (Japan), Dr. Naoshi Nishida (Japan),
Dr. Akinobu Taketomi (Japan)*

9:10-9:22 WS4-1

Immunoglobulin-like Transcript 2 as an Impaired Anti-tumor Cytotoxicity Marker of Natural Killer Cells in Patients with Hepatocellular Carcinoma

Dr. Sachiyo Yoshio (Japan)

9:22-9:34 WS4-2

Novel Monoclonal Antibody and ADAM17 Enzymatic Inhibitor could Induce NK Cell-mediated Cytotoxicity in HCC by Targeting NKG2D Ligands

Dr. Jun Arai (Japan)

9:34-9:46 WS4-3

Fibroblast Growth Factor Inhibition by Molecular-targeted Agents Mitigates Immuno-suppressive Tissue Microenvironment in Hepatocellular Carcinoma

Dr. Hiroyuki Suzuki (Japan)

9:46-9:58 WS4-4

Prevention of Liver Carcinogenesis by Glycine in Hepatocyte-specific PTEN Knockout Mice

Dr. Kazuyoshi Kon (Japan)

10:10-11:10 Workshop 5: Basic Science & Pathology 2

*Chairs: Dr. Lai Wei (China), Dr. Hayato Hikita (Japan), Dr. Hironori Koga (Japan),
Dr. Masashi Ninomiya (Japan)*

10:10-10:22 WS5-1

Intrahepatic IgA Complex Induces Polarization of Cancer Associated Fibroblasts into the Matrix Phenotype in the Tumor Microenvironment of HCC

Dr. Pil Soo Sung (Korea)

10:22-10:34 WS5-2

The role and Mechanism of LincRNA Encoded Peptide in the Progression of Hepatocellular Carcinoma

Dr. Guang-Zhi Jin (China)

10:34-10:46 WS5-3

Interaction between HSC and LSEC Populations in the Premalignant Environment of DEN-treated Cytochrome Knock-out Mice

Dr. Ha T. Nguyen (Japan)

10:46-10:58 WS5-4

Anti-proliferative Effects of a Flavonoid from *Anomianthus dulcis* Sincl. on Hepatocellular Carcinoma

Dr. Charupong Saengboonmee (Thailand)

10:58-11:10 WS5-5

Protective Effect of Ischemic Preconditioning on Hepatic Ischemia-reperfusion Injury in Rats

Dr. Naoki Hashimoto (Japan)

11:40-12:00 Keynote Lecture 4

Chair: Nobuyuki Enomoto (Japan)

Strategies for Terminating HBV related HCC

Dr. Man Fung Yuen (China)

12:30-13:30 Luncheon Seminar 2 (by Chugai Pharmaceutical Co., Ltd.)

Chair: Dr. Tatsuya Yamashita (Japan)

Unlocking the Potential of Combination Immunotherapy in Advanced Hepatocellular Carcinoma

Dr. Sadahisa Ogasawara (Japan)

15:20-15:40 Keynote Lecture 5

Chair: Jun Inoue (Japan)

Deciphering HCC Risk Scores for Chronic Hepatitis B

Dr. Henry L.Y. Chan (China)

15:40-16:40 Workshop 6: Basic Science & Pathology 3

Chairs: Dr. Jose Sollano (Philippines), Dr. Takahiro Kodama (Japan),

Dr. Sadahisa Ogasawara (Japan), Dr. Masahito Shimizu (Japan)

15:40-15:52 WS6-1

Enhancing Tumor Immunogenicity of Hepatocellular Carcinoma using a Novel Cancer Vaccine

Dr. Masao Nakajima (Japan)

15:52-16:04 WS6-2

High-grade Nuclear Atypia is an Unfavorable Factor for Postoperative Recurrence of Hepatocellular Carcinoma

Dr. Shinji Mizuochi (Japan)

16:04-16:16 WS6-3

Findings of Liver Pathology in Autopsy

Dr. Amar Ranjan (India)

16:16-16:18 WS6-4

Significance of Partial Portal Arterialization in Small Bowel Transplantation for the Liver

Dr. Naoki Hashimoto (Japan)

Day 2: October 28 (Saturday) 2023

Room 1 (Sendai A)

8:00-9:00 Morning Seminar 1 (Sponsored by Gilead Sciences K.K.)

Chair: Dr. Hidekatsu Kuroda (Japan)

A New Era in Liver Diseases: Recent Advances and Issues in Hepatitis C Virus Infection and Liver Cancer

Dr. Jun Inoue

9:10-10:10 Workshop 7: Systemic Chemotherapy & Oncology 3

Chairs: Dr. Tawesak Tanwandee (Thailand), Dr. Yosuke Nakai (Japan),

Dr. Motoyuki Otsuka (Japan), Dr. Kaoru Tsuchiya (Japan)

9:10-9:22 WS7-1

A Prospective Study to Assess the Safety and Efficacy of Ramucirumab in Advanced Hepatocellular Carcinoma Patients in Japanese Real-world Practice: R-evolution Study

Dr. Kazufumi Kobayashi (Japan)

9:22-9:34 WS7-2

A Randomized Phase II Trial to Assess Safety and Efficacy of Regorafenib in Patients with Advanced Hepatocellular Carcinoma who were not Included in the RESORCE Trial: REGAIN Trial

Dr. Keisuke Koroki (Japan)

9:34-9:46 WS7-3

Efficacy of Lenvatinib Combined with Transcatheter Intraarterial Therapies for Patients with Advanced-stage of Hepatocellular Carcinoma: A Propensity Score Matching

Dr. Shigeo Shimose (Japan)

9:46-9:58 WS7-4

The Effectiveness of Durvalumab plus Tremelimumab Treatment for Hepatocellular Carcinoma after Treatment with Anti-VEGF Drugs

Dr. Takayoshi Oikawa (Japan)

9:58-10:10 WS7-5

Early Experience of Durvalumab plus Tremelimumab in Patients with Unresectable Hepatocellular Carcinoma

Dr. Kaoru Tsuchiya (Japan)

10:20-11:20 Workshop 8: Systemic Chemotherapy & Oncology 4

*Chairs: Dr. Ji—Dong Jia (China), Dr. Atsushi Hiraoka (Japan), Dr. Taro Takami (Japan),
Dr. Kazuomi Ueshima (Japan)*

10:20-10:32 WS8-1

Survival Improvements in Advanced Hepatocellular Carcinoma with Systemic Therapy Over the Past Decade

Dr. Ryo Yano (Japan)

10:32-10:44 WS8-2

Association between Presarcopenia and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Systemic Therapy: A Comprehensive Study and Meta-Analysis

Dr. Ching-Sheng Hsu (Taiwan)

10:44-10:56 WS8-3

Consistent Efficacy of Hepatic Artery Infusion Chemotherapy Irrespective of PD-L1 Positivity in Unresectable Hepatocellular Carcinoma

Dr. Pil Soo Sung (Korea)

10:56-11:08 WS8-4

Genetic Discrimination between MC and IM could be Useful in Planning Tumor-specific Treatment Strategies for Recurrent Hepatocellular Carcinoma

Dr. Yuji Iimuro (Japan)

11:08-11:20 WS8-5

Abdominal Pain Accompanied by Elevated Serum Inflammatory Markers and Biliary Enzymes for Diagnosing Immune Checkpoint Inhibitor-induced Sclerosing Cholangitis

Dr. Takanori Ito (Japan)

11:30-11:50 Keynote Lecture 6

Chair: Dr. Naoya Kato (Japan)

Molecular Mechanisms and Cellular Origins of Biliary Tract Cancer: Cutting-edge Knowledge from Mouse Models

Dr. Hayato Nakagawa (Japan)

11:50-12:10 Keynote Lecture 7

Chair: Dr. Yasuhito Tanaka (Japan)

Strategies for Terminating HCV-related HCC

Dr. Mindie H. Nguyen (USA)

12:30-13:30 Luncheon Seminar 3 (Sponsored by Gilead Sciences K.K. Medical Affairs)

Chair: Dr. Motoyuki Otsuka (Japan)

Recent Topics about Hepatocellular Carcinoma: Focusing on Risks of Hepatitis and Advances in the Therapy

Dr. Masayuki Kurosaki (Japan)

13:40-14:25 Special Lecture 4

Chair: Dr. Tetsuo Takehara (Japan)

All Stages of HCC Patients Benefit from Systemic Therapy Combined with Locoregional Therapy

Dr. Masatoshi Kudo (Japan)

14:35-15:35 Workshop 9: Hepatitis C, Hepatitis B

*Chairs: Dr. Barjesh C. Sharma (India), Dr. Hirayuki Enomoto (Japan), Dr. Tatsuya Kanto (Japan),
Dr. Takeshi Umemura (Japan)*

14:35-14:47 WS9-1

Usefulness of FIB-4 Index and ALT at 1 Year of Nucleos(t)ide Analog Treatment for Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

Dr. Jun Inoue (Japan)

14:47-14:59 WS9-2

MxB Induced in Mitochondria by IFN Inhibits HBV Replication by Activating the RIG-I Signaling Pathway

Dr. Masazumi Onuki (Japan)

14:59-15:11 WS9-3

HCV Clearance Improves Amino Acids Imbalance in Patients with Hepatitis C Regardless of the Presence of Advanced Fibrosis or Previous Treatment of HCC

Dr. Masaaki Mino (Japan)

15:11-15:23 WS9-4

Clinical and Imaging Features of Hypervascular De Novo Hepatocellular Carcinoma after HCV Eradication

Dr. Tomoko Tanaka (Japan)

15:23-15:35 WS9-5

Recurrence and Prognosis of Patients with Primary Hepatocellular Carcinoma Treated with Radiofrequency Ablation

Dr. Rie Goka (Japan)

15:45-16:45 Workshop 10: Radiotherapy, Imaging & Diagnosis, irAE

*Chairs: Dr. A Kadir Dokmeci (Turkey), Dr. Teiji Kuzuya (Japan), Dr. Shuuichiro Shiina (Japan),
Dr. Ryosuke Tateishi (Japan)*

15:45-15:57 WS10-1

**Effectiveness of Repeated Stereotactic Body Radiation Therapy for
Hepatocellular Carcinoma**

Dr. Tomokazu Kawaoka (Japan)

15:57-16:09 WS10-2

**Establishment of Hepatic Tumor Differentiation and Hepatocellular Carcinoma
Grading Method by Quantitative Analysis of Contrast-enhanced Ultrasound
Images Using Microbubbles**

Dr. Tamami Abe (Japan)

16:09-16:21 WS10-3

**Differentiation of AST/ALT Elevation during Immunotherapy in Patients with
Advanced Hepatocellular Carcinoma and Other Cancers**

Dr. Ryo Izai (Japan)

16:21-16:33 WS10-4

**The Current Status of IMH in Our Hospital and Experience with the Use of
Tacrolimus in Cases Resistant to PSL and MMF**

Dr. Mio Tsuruoka (Japan)

16:33-16:45 WS10-5

**Current Status of Tumor Ablation in Japan and Establishment of the Japan
Academy of Tumor Ablation (JATA)**

Dr. Shuichiro Shiina (Japan)

16:45-16:55 Closing Ceremony

Closing Remarks: Dr. Yoshiyuki Ueno, President of APASL Oncology 2023 Sendai

Day 2: October 28 (Saturday) 2023

Room 2 (Sendai B)

9:10-10:10 Workshop 11: Surgery & Transplantation

Chairs: Dr. Rino Gani (Indonesia), Dr. Nobuhisa Akamatsu (Japan),

Dr. Kiyoshi Hasegawa (Japan), Dr. Takayoshi Oikawa (Japan)

9:10-9:22 WS11-1

Choosing Alternative Conduit in Unusable Recipient's Hepatic Artery for Liver Transplantation: A Risk Benefit Analysis Based on Systematic Review and Bayesian Network-Meta Analysis

Dr. Citra Aryanti (Indonesia)

9:22-9:34 WS11-2

Difficulty in Survival Prediction for Hepatocellular Carcinoma and Cholangiocarcinoma after Orthotopic Liver Transplantation

Dr. Akinobu Takaki (Japan)

9:34-9:46 WS11-3

Strategy of Living Donor Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

Dr. Takashi Ito (Japan)

9:46-9:58 WS11-4

Strategy for Liver Transplantation with Marginal Donor for HCC Cases

Dr. Kazuaki Tokodai (Japan)

9:58-10:10 WS11-5

Laparoscopic Left Medial Sectionectomy According to Tumor Localization

Dr. Yukio Tokumitsu (Japan)

10:20-11:20 Workshop 12: Surgery & Transplantation, TACE, HAIC & Vascular Interventions

Chairs: Dr. Darrell Crawford (Australia), Dr. Michiie Sakamoto (Japan),

Dr. Shinji Tanaka (Japan), Dr. Michiaki Unno (Japan)

10:20-10:32 WS12-1

The Impact of Local Ablation in Resected Hepatocellular Carcinoma

Dr. Yusuke Nishi (Japan)

10:32-10:44 WS12-2

Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma

Dr. Norifumi Iseda (Japan)

10:44-10:56 WS12-3

Hyperamylasemia after Hepatic Resection

Dr. Naoki Hashimoto (Japan)

10:56-11:08 WS12-4

The Effectiveness of the Locoregional Treatment Using Hepatic Arterial Infusion Chemotherapy New FP for Locally Progressed Hepatocellular Carcinoma

Dr. Hideki Iwamoto (Japan)

11:08-11:20 WS12-5

Effect of Distal Splenorenal Shunt plus Splenopancreatic Disconnection on Glucose and Amino Acid Metabolism

Dr. Naoki Hashimoto (Japan)

11:50-12:10 Keynote Lecture 8

Chair: Dr. Hiromichi Isayama (Japan)

RNA Therapeutics for Liver Cancers

Dr. Tushar Patel (USA)

12:30-13:30 Luncheon Seminar 4 (Sponsored by AbbVie GK)

Chair: Dr. Naoya Sakamoto (Japan)

Multidisciplinary Treatment Including DEB-TACE Combined with HAIC and iCIs should be Considered to Control HCC ~Including Patients after DAA Treatment~

Dr. Yasuteru Kondo (Japan)

14:35-15:47 Workshop 13: Tumor Markers & Biochemistry, CCC, Others

Chairs: Dr. Cosmas A. Lesmana (Indonesia), Dr. Tatsuo Kanda (Japan),

Dr. Tsutomu Masaki (Japan), Dr. Kazuhiro Nouso (Japan)

14:35-14:47 WS13-1

Diagnostic Value of Serum GPC3 in Early Stage of HCC

Dr. Munkhbayar Semchin (Mongolia)

14:47-14:59 WS13-2

Metabolic Profiling Identifies Key Metabolic Biochemical Pathways Associated with Recurrence of Hepatocellular Carcinoma

Dr. Hongping Xia (Singapore)

14:59-15:11 WS13-3

The Bile Level of Cytokeratin 7 as a Diagnostic Marker for Cholangiocarcinoma

Dr. Alzhraa Alkhatib (Egypt)

15:11-15:23 WS13-4

The Effects of Hepatic Arterial Infusion on Survival in Patients with Intrahepatic Cholangiocarcinoma: A Meta-Analysis

Dr. Edwin N. Njoto (Indonesia)

15:23-15:35 WS13-5

Efficacy of NewFP Therapy for Unresectable Advanced Intrahepatic Cholangiocarcinoma

Dr. Hiroto Ota (Japan)

15:35-15:47 WS13-6

Support and Implementation system for Clinical Cancer Research at the Prefectural Designated Regional Cancer Centers and Hospital

Dr. Kenji Amemiya (Japan)